{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:58:57Z","timestamp":1792616337796,"version":"4.5.0"},"reference-count":86,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec id=\"ab-crv240010-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Central nervous system (CNS) metastases presenting as either brain parenchymal metastases or leptomeningeal metastases are diagnosed in up to 50% of patients with advanced non\u2013small cell lung cancer during their disease course. While historically associated with a poor prognosis due to limited treatment options, the availability of an increasing number of targeted therapies with good CNS penetration has significantly improved clinical outcomes for these patients. This has occurred in parallel with a more nuanced understanding of prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv240010-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Multiple clinical trials have reported that disease control can be observed with targeted therapies with adequate CNS penetration, particularly for patients with molecular alterations in EGFR, ALK, ROS1, and RET. For these tumors, systemic targeted therapy may be used first for the management of CNS metastases, prior to considering radiation therapy (RT). At the time of isolated progression in the CNS, RT may be considered for the progressing lesions with continuation of the same systemic therapy. For other molecular alterations as well as for patients treated with checkpoint inhibitors, data are not yet clear if systemic therapy is sufficient for untreated CNS metastases, and early RT may need to be integrated into the treatment planning. An increasing number of studies investigate the role that emerging techniques, such as the sequencing of tumor DNA from resected brain metastases tissue or cerebrospinal fluid or radiomics-based analysis of CNS imaging, can play in guiding treatment approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-crv240010-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>With multiple generations of targeted therapies now available, the treatment for CNS metastases should be tailored to the patients with consideration given to molecular testing results, CNS penetrance of systemic therapy, patient characteristics, and multidisciplinary review. More research is needed in understanding the clonal evolution of CNS metastases, and the development of novel therapeutics with CNS efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.5218","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:34:23Z","timestamp":1732707263000},"page":"60","source":"Crossref","is-referenced-by-count":22,"title":["Targeting CNS Metastases in Non\u2013Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers"],"prefix":"10.1001","volume":"11","author":[{"given":"Jyoti","family":"Malhotra","sequence":"first","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Mambetsariev","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Gilmore","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Fricke","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arin","family":"Nam","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gallego","sequence":"additional","affiliation":[{"name":"Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihong T.","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Amini","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas V.","family":"Lukas","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"crv240010r1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"12","key":"crv240010r2","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.3390\/jcm12123901","article-title":"Building team medicine in the management of CNS metastases.","volume":"12","author":"Baskaran","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"crv240010r3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/cns.13.66","article-title":"Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.","volume":"3","author":"Lukas","year":"2014","journal-title":"CNS Oncol"},{"issue":"3","key":"crv240010r4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/biom12030401","article-title":"Brain vascular microenvironments in cancer metastasis.","volume":"12","author":"Tobar","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"crv240010r5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10585-010-9354-8","article-title":"Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis.","volume":"28","author":"Seike","year":"2011","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"crv240010r6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12987-023-00482-9","article-title":"A tissue-engineered model of the blood-tumor barrier during metastatic breast cancer.","volume":"20","author":"Linville","year":"2023","journal-title":"Fluids Barriers CNS"},{"issue":"11","key":"crv240010r7","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central nervous system cancers, version 3.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"18","author":"Nabors","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"crv240010r8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis.","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"key":"crv240010r9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621088","article-title":"Predicting survival duration with MRI radiomics of brain metastases from non-small cell lung cancer.","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"crv240010r10","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat Commun"},{"issue":"9","key":"crv240010r11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"crv240010r12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/b104814","article-title":"Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging.","volume":"125","author":"Enting","year":"2005","journal-title":"Cancer Treat Res"},{"issue":"2","key":"crv240010r13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.21037\/tlcr-21-62","article-title":"Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis.","volume":"10","author":"Liu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"crv240010r14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.","volume":"29","author":"Li","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"crv240010r15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA).","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"crv240010r16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","article-title":"Graded prognostic assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors.","volume":"114","author":"Sperduto","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"crv240010r17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae insights: central nervous system cancers, version 2.2022.","volume":"21","author":"Horbinski","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"crv240010r18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial.","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"crv240010r19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.6186","article-title":"Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial.","author":"Kayama","journal-title":"J Clin Oncol"},{"issue":"8","key":"crv240010r20","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"crv240010r21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"crv240010r22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial.","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"crv240010r23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"issue":"34","key":"crv240010r24","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","article-title":"Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.","volume":"32","author":"Gondi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"crv240010r25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001.","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv240010r26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","article-title":"Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro Oncol"},{"issue":"33","key":"crv240010r27","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.22.01148","article-title":"Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"crv240010r28","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937953","article-title":"Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I\/II study.","volume":"12","author":"Pan","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"crv240010r29","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets.","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"issue":"6","key":"crv240010r30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3171\/jns.2006.104.6.907","article-title":"Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin.","volume":"104","author":"Vogelbaum","year":"2006","journal-title":"J Neurosurg"},{"key":"crv240010r31","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How we treat patients with leptomeningeal metastases.","volume":"4","author":"Le Rhun","year":"2019","journal-title":"ESMO Open"},{"issue":"1","key":"crv240010r32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000066520","article-title":"Front-line paclitaxel\/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.","volume":"64","author":"Cortes","year":"2003","journal-title":"Oncology"},{"issue":"2","key":"crv240010r33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3892\/ol.2016.4783","article-title":"Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis.","volume":"12","author":"Wu","year":"2016","journal-title":"Oncol Lett"},{"issue":"8","key":"crv240010r34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","article-title":"Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC\u2014a prospective, open-label, single-arm phase 1\/2 clinical trial.","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"crv240010r35","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.cllc.2022.11.011","article-title":"Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase I study.","volume":"24","author":"Li","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"crv240010r36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"crv240010r37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics.","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol"},{"issue":"26","key":"crv240010r38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2217\/fon-2022-0926","article-title":"Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors.","volume":"19","author":"Baskaran","year":"2023","journal-title":"Future Oncol"},{"issue":"10","key":"crv240010r39","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"crv240010r40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer.","author":"Reungwetwattana","journal-title":"J Clin Oncol"},{"issue":"2","key":"crv240010r41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"crv240010r42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1759-7714.13738","article-title":"Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: a phase II single-arm prospective clinical trial.","volume":"12","author":"Lu","year":"2021","journal-title":"Thorac Cancer"},{"issue":"4","key":"crv240010r43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis.","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"12","key":"crv240010r44","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-21-1838","article-title":"ASCEND-7: efficacy and safety of ceritinib treatment in patients with ALK-positive non-small cell lung cancer metastatic to the brain and\/or leptomeninges.","volume":"28","author":"Chow","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"crv240010r45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer.","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"crv240010r46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"31","key":"crv240010r47","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study.","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv240010r48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial.","volume":"15","author":"Huber","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"6","key":"crv240010r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC.","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"16","key":"crv240010r50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9017","article-title":"Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1\/2 TRIDENT-1.","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv240010r51","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/j.jtho.2021.01.251","article-title":"MA11.07 phase 1\/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors.","volume":"16","author":"Cho","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"15","key":"crv240010r52","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial.","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"crv240010r53","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer.","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"crv240010r54","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study.","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"crv240010r55","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer.","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"crv240010r56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9084","article-title":"Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.","volume":"39","author":"Patel","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"crv240010r57","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations.","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"28","key":"crv240010r58","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of Adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non-small-cell lung cancer who have untreated CNS metastases.","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"crv240010r59","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"issue":"1","key":"crv240010r60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cncr.30990","article-title":"Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.","volume":"124","author":"Arbour","year":"2018","journal-title":"Cancer"},{"issue":"20","key":"crv240010r61","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity.","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"crv240010r62","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study.","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv240010r63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s40001-023-01219-y","article-title":"Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis.","volume":"28","author":"Wen","year":"2023","journal-title":"Eur J Med Res"},{"issue":"30","key":"crv240010r64","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"issue":"26","key":"crv240010r65","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, tolerability, and antitumor activity of zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions.","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"crv240010r66","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"crv240010r67","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer.","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"crv240010r68","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.","volume":"32","author":"Felip","year":"2021","journal-title":"Ann Oncol"},{"key":"crv240010r69","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00522","article-title":"Phase II study of lorlatinib in patients with anaplastic lymphoma kinase-positive lung cancer and CNS-specific relapse.","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"crv240010r70","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jtho.2015.10.010","article-title":"Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib.","volume":"11","author":"Gainor","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"4","key":"crv240010r71","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae insights: non-small cell lung cancer, version 2.2023.","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"crv240010r72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/PO.19.00021","article-title":"Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases.","volume":"3","author":"Guo","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"crv240010r73","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.cllc.2021.06.005","article-title":"Central nervous system response to selpercartinib in patient with RET-rearranged non-small cell lung cancer after developing leptomeningeal disease on pralsetinib.","volume":"23","author":"Tsui","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"20","key":"crv240010r74","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/cncr.34897","article-title":"Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.","volume":"129","author":"Zhou","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"crv240010r75","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"crv240010r76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis.","volume":"17","author":"Planchard","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"21","key":"crv240010r77","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer.","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"crv240010r78","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00621","article-title":"Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRASG12C-mutant non-small-cell lung cancer.","volume":"7","author":"Lamberti","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"13","key":"crv240010r79","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer.","volume":"63","author":"Fell","year":"2020","journal-title":"J Med Chem"},{"issue":"15","key":"crv240010r80","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer.","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"crv240010r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.547","article-title":"P52.03 efficacy of sotorasib in KRAS p.G12C-mutated NSCLC with stable brain metastases: a post-hoc analysis of CodeBreaK 100.","volume":"16","author":"Ramalingam","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"13","key":"crv240010r82","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/CM9.0000000000002163","article-title":"Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.","volume":"136","author":"Wei","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"crv240010r83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100205","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042.","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"crv240010r84","doi-asserted-by":"publisher","first-page":"II28","DOI":"10.1093\/annonc\/mdx091.001","article-title":"Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases.","volume":"28","author":"Lukas","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"crv240010r85","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","article-title":"Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous nsclc with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2 study.","volume":"18","author":"Hou","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"8","key":"crv240010r86","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 Part 1.","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2827108\/jamaoncology_malhotra_2024_rv_240010_1735837182.05209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:01:17Z","timestamp":1737025277000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2827108"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.5218","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}